[Viral hepatitis B/C and HIV. Therapy of double infections].
In patients with HIV coinfection, chronic hepatitis B was initially treated with interferon alpha, but the long-term results were disappointing. Currently, pegylated interferon is being investigated in an ongoing study. The nucleoside analogues lamivudine and adefovir may well become established as alternatives to interferon alpha. Treatment of hepatitis C in HIV coinfection with interferon alpha plus ribavirin also proved less efficacious compared to HCV-monoinfection. Initial preliminary results of studies on pegylated interferon alpha indicate an advantage over conventional interferon. Under treatment for hepatitis metabolic acidosis and hepatic decompensation may occur--in particular with didanosine and/or stavudine--and these substances may therefore be avoided as antiretroviral therapy in dual infection with hepatitis and HIV.
Mauss
S
S
Zentrum Für HIV und Hepatogastroenterologie, Düsseldorf.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000225:Adenine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D019259:Lamivudine / Q000008:administration & dosage* / Q000009:adverse effects; D063065:Organophosphonates; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D016898:Interferon-alpha; D063065:Organophosphonates; D019259:Lamivudine; C053001:adefovir; D000225:Adenine